BRIEF-Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96

Oct 17 (Reuters) – AbbVie Inc.: * ABBVIE – RISANKIZUMAB IN ULCERATIVE COLITIS SHOWS CLINICAL REMISSION RATES OF 54.0%-73.1% AT WEEK 96 * ABBVIE – UPADACITINIB IN CROHN'S DISEASE SHOWS CLINICAL

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)